Ex. 2066 - Settlement Agreement [CONFIDENTIAL] | Nov 27, 2018 | EXHIBIT | PATENT OWNER |
Joint Motion to Terminate | Nov 27, 2018 | PAPER | PATENT OWNER |
Joint Request to File Settlement Confidential | Nov 27, 2018 | PAPER | PATENT OWNER |
Decision - 37 C.F.R. 42.74 | Nov 27, 2018 | PAPER | BOARD |
Termination Decision Document | Nov 27, 2018 | PAPER | BOARD |
Hearing Transcript | Sep 27, 2018 | PAPER | BOARD |
Petitioners' Objections to Patent Owners' Demonstratives | Aug 31, 2018 | PAPER | PETITIONER |
Petitioners' Demonstrative Exhibits Oral Argument | Aug 31, 2018 | EXHIBIT | PETITIONER |
Patent Owner's Objections to Petitioner's Demonstratives | Aug 31, 2018 | PAPER | PATENT OWNER |
Patent Owner's Demonstrative Exhibits | Aug 31, 2018 | EXHIBIT | PATENT OWNER |
Petitioners' Reply in Support of Their Motion to Exclude Evidence | Aug 21, 2018 | PAPER | PETITIONER |
Patent Owners' Reply In Further Support of Their Motion to Exclude | Aug 21, 2018 | PAPER | PATENT OWNER |
Order - Trial Hearing | Aug 21, 2018 | PAPER | BOARD |
ORDER Conduct of the Proceeding | Aug 13, 2018 | PAPER | BOARD |
Patent Owners' Opposition to Petitioners' Motion to Exclude | Aug 9, 2018 | PAPER | PATENT OWNER |
Ex. 2053 - Tafluprost PMDA Entry | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Petitioners¿¿¿ Response to Patent Owners¿¿¿ Motion for Observation Regarding Cross-Examination of Petitioners¿¿¿ Expert, Dr. Mitchell A. deLong | Aug 9, 2018 | PAPER | PETITIONER |
Exhibit 1064 - Primary care optometry news. - NLM Catalog - NCBI | Aug 9, 2018 | EXHIBIT | PETITIONER |
Patent Owner's Third Updated Exhibit List | Aug 9, 2018 | PAPER | PATENT OWNER |
Ex. 2051 - WestLaw Version of Alcon Canada v. Apotex | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Ex. 2052 - CA Federal Court link to Alcon Canada v. Apotex | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Ex. 2054 - Tapros Drug Information Sheet | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Ex. 2055 - Tapros Package Insert | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Petitioners¿¿¿ Response to Patent Owners¿¿¿ Motion for Observation Regarding Cross-Examination of Petitioners¿¿¿ Expert, Dr. Aron D. Rose | Aug 9, 2018 | PAPER | PETITIONER |
Petitioners¿¿¿ Opposition to Patent Owners¿¿¿ Motion to Exclude | Aug 9, 2018 | PAPER | PETITIONER |
Petitioners¿¿¿ Updated Exhibit List | Aug 9, 2018 | PAPER | PETITIONER |
Exhibit 1063 - Kubinyi1979 - Progress in Drug research 23 97 (1979) | Aug 9, 2018 | EXHIBIT | PETITIONER |
Petitioners' Motion to Exclude Evidence | Jul 26, 2018 | PAPER | PETITIONER |
Petitioners' Request for Oral Argument | Jul 26, 2018 | PAPER | PETITIONER |
Patent Owners' Motion for Observation - Rose | Jul 26, 2018 | PAPER | PATENT OWNER |
Patent Owners' Motion to Exclude | Jul 26, 2018 | PAPER | PATENT OWNER |
Patent Owners' Request for Oral Argument | Jul 26, 2018 | PAPER | PATENT OWNER |
Patent Owners' Motion for Observation - deLong | Jul 26, 2018 | PAPER | PATENT OWNER |
Patent Owner's Second Updated Exhibit List | Jul 26, 2018 | PAPER | PATENT OWNER |
Ex. 2056 - Human Metabolome Database - tafluprost | Jul 26, 2018 | EXHIBIT | PATENT OWNER |
Ex. 2057 - Human Metabolome Database - latanoprost | Jul 26, 2018 | EXHIBIT | PATENT OWNER |
Ex. 2058 - Rulo 1994 | Jul 26, 2018 | EXHIBIT | PATENT OWNER |
Ex. 2059 - Villumsen and Alm 1992 | Jul 26, 2018 | EXHIBIT | PATENT OWNER |
Ex. 2060 - Xalatan label, Nov. 26, 2001 | Jul 26, 2018 | EXHIBIT | PATENT OWNER |
Ex. 2061 - deLong Transcript II | Jul 26, 2018 | EXHIBIT | PATENT OWNER |
Ex. 2062 - Rose Transcript II | Jul 26, 2018 | EXHIBIT | PATENT OWNER |
Ex. 2063 - Human Metabolome Database - tafluprost (replacement for Ex. 2056) | Jul 26, 2018 | EXHIBIT | PATENT OWNER |
Ex. 2064 - Human Metabolome Database - latanoprost (replacement for Ex. 2057) | Jul 26, 2018 | EXHIBIT | PATENT OWNER |
Patent Owners' Notice of Deposition - deLong | Jun 22, 2018 | PAPER | PATENT OWNER |
Patent Owners' Notice of Deposition - Rose | Jun 22, 2018 | PAPER | PATENT OWNER |
Patent Owners' Objections to Evidence | Jun 12, 2018 | PAPER | PATENT OWNER |
Kerstetter, J.R. et al., ¿¿¿Prostaglandin F2¿¿-1-Isopropylester Lowers Intraocular Pressure Without Decreasing Aqueous Humor Flow,¿¿¿ American Journal of Ophthalmology, Vol. 105, No. 1, 30¿¿¿34 (1988). | Jun 5, 2018 | EXHIBIT | PETITIONER |
Villumsen, Jorgen et al., ¿¿¿Prostaglandin F2¿¿-isopropylester eye drops: effect on intraocular pressure in open-angle glaucoma,¿¿¿ Br. J. Opthalmol. 73:975¿¿¿979 (1989). | Jun 5, 2018 | EXHIBIT | PETITIONER |
Camras et al., ¿¿¿Latanoprost, a Prostaglandin Analog, for Glaucoma Therapy: efficacy and safety after 1 year of treatment in 198 patients,¿¿¿ Ophthalmology, 103:1916¿¿¿1924 (November 1996). | Jun 5, 2018 | EXHIBIT | PETITIONER |
Camras C.B. et al., ¿¿¿Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States,¿¿¿ Ophthalmology, 103(1):138¿¿¿47 (January 1996). | Jun 5, 2018 | EXHIBIT | PETITIONER |
Petitioners' Reply to Patent Owner Brief | Jun 5, 2018 | PAPER | PETITIONER |
Supplemental Declaration of Mitchell A. deLong, Ph.D. | Jun 5, 2018 | EXHIBIT | PETITIONER |
Supplemental Declaration of Aron D. Rose, M.D. | Jun 5, 2018 | EXHIBIT | PETITIONER |
U.S. Patent No. 5,296,504 to Stjernschantz et al., issued March 22, 1994. | Jun 5, 2018 | EXHIBIT | PETITIONER |
Alm A., ¿¿¿Latanoprost in the treatment of glaucoma,¿¿¿ Clin. Ophthalmol., 8:1967¿¿¿85 (2014). | Jun 5, 2018 | EXHIBIT | PETITIONER |
Alan Robin, MD, ¿¿¿Two new options will make glaucoma therapy safer,¿¿¿ Primary Care Optometry News, July 1996. | Jun 5, 2018 | EXHIBIT | PETITIONER |
Mishima, Hiromu K., et al., ¿¿¿Circadian Intraocular Pressure Management with Latanoprost: Diurnal and Nocturnal Intraocular Pressure Reduction and Increased Uveoscleral Outflow,¿¿¿ Survey of Ophthalmology, vol. 41:2 (Feb. 1997). | Jun 5, 2018 | EXHIBIT | PETITIONER |
Konstas, Anatasios G P et al. ¿¿¿Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension,¿¿¿ Br. J. Opthalmol. 97:1510¿¿¿1515 (2013). | Jun 5, 2018 | EXHIBIT | PETITIONER |
Ikeda, Yoko et al. ¿¿¿Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma,¿¿¿ Clinical Ophthalmology, 10:1633¿¿¿1637 (2016). | Jun 5, 2018 | EXHIBIT | PETITIONER |
Lee P-Y et al., ¿¿¿Effect of prostaglandin F2¿¿ on aqueous humor dynamics of rabbit, cat, and monkey,¿¿¿ Invest Ophthalmol Vis Sci, 25:1087¿¿¿1093 (1984). | Jun 5, 2018 | EXHIBIT | PETITIONER |
Husain S. et al., ¿¿¿Latanoprost-Induced Changes in Rat Intraocular
Pressure: Direct or Indirect ?¿¿¿ J. Ocul. Pharmacol. Ther., 24(4):367¿¿¿372 (2008). | Jun 5, 2018 | EXHIBIT | PETITIONER |
Resul B. et al., ¿¿¿Phenyl-Substituted Prostaglandins: Potent and Selective Antiglaucoma Agents,¿¿¿ J. Med. Chem., 36:243¿¿¿248 (1993). | Jun 5, 2018 | EXHIBIT | PETITIONER |
Skuballa W. et al., ¿¿¿15, 15-Ketals of Natural
Prostaglandins and Prostaglandin Analogues. Synthesis and Biological Activities,¿¿¿ J. Med. Chem. 21:443¿¿¿447 (1978). | Jun 5, 2018 | EXHIBIT | PETITIONER |
deLong M.A., ¿¿¿Seminar on Lipophilicity including
a method for estimating the logP of organic compounds,¿¿¿ Lecture notes follow circa 1989, Stanford University. | Jun 5, 2018 | EXHIBIT | PETITIONER |
Fogagnolo, Paolo et al. ¿¿¿A 1-Year Randomized Study of the Clinical and Confocal Effects of Tafluprost and Latanoprost in Newly Diagnosed Glaucoma Patients,¿¿¿ Adv. Ther., 32:356¿¿¿369 (2015). | Jun 5, 2018 | EXHIBIT | PETITIONER |
Patel S.S. et al., ¿¿¿Latanoprost: A Review of its Pharmacological Properties, Clinical Efficacy and Tolerability in the Management of Primary Open-Angle. Glaucoma and Ocular Hypertension,¿¿¿ Drugs Aging, 9(5):363¿¿¿78 (November 1996). | Jun 5, 2018 | EXHIBIT | PETITIONER |
Bito L.Z., ¿¿¿Comparison of the Ocular Hypotensive Efficacy of Eicosanoids and Related Compounds,¿¿¿ Exp. Eye Res., 38(2):181¿¿¿94 (1984). | Jun 5, 2018 | EXHIBIT | PETITIONER |
Judith A.K. Howard et al., ¿¿¿How Good is Fluorine as a
Hydrogen Bond Acceptor?¿¿¿ Tetrahedron, 52:12613¿¿¿12622 (Sept. 1996). | Jun 5, 2018 | EXHIBIT | PETITIONER |
Latanoprost DrugBank Profile, available at https://www.drugbank.ca/drugs/DB00654 (last visited May 31, 2018). | Jun 5, 2018 | EXHIBIT | PETITIONER |
Santen Pharmaceutical Co., Ltd. Annual Report 2013 | Jun 5, 2018 | EXHIBIT | PETITIONER |
Santen Pharmaceutical Co., Ltd. Data Book Year Ended March 31, 2016. | Jun 5, 2018 | EXHIBIT | PETITIONER |
Exhibit 1055 - GlobalData Healthcare (2018) | Jun 5, 2018 | EXHIBIT | PETITIONER |
Exhibit 1056 - Aerie Pharmaceuticals, Inc. Form 8-K (2018) | Jun 5, 2018 | EXHIBIT | PETITIONER |
Petitioners' Updated Exhibit List | Jun 5, 2018 | PAPER | PETITIONER |
Exhibit 1057 - Aerie Pharmaceuticals, Inc. Form 8-K (2017) | Jun 5, 2018 | EXHIBIT | PETITIONER |
Santen Pharmaceutical Co., Ltd. Data Book (2015) | Jun 5, 2018 | EXHIBIT | PETITIONER |
Exhibit 1059 - Santen Pharmaceutical Co., Ltd. Data Book (2017) | Jun 5, 2018 | EXHIBIT | PETITIONER |
Exhibit 1060 - Santen Pharmaceutical Co., Ltd. Annual Report (2014) | Jun 5, 2018 | EXHIBIT | PETITIONER |
Exhibit 1061 - U.S. Patent No. 4,599,353 to Bito L.Z. (1986) | Jun 5, 2018 | EXHIBIT | PETITIONER |
Exhibit 1062 - Appendix B to Exhibit 1032 | Jun 5, 2018 | EXHIBIT | PETITIONER |
Petitioners' Updated Exhibit List | Jun 5, 2018 | PAPER | PETITIONER |
Petitioners' Objections to Evidence | Mar 12, 2018 | PAPER | PETITIONER |
Ex.2025 - deLong Transcript | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Ex.2026 - Rose Transcript | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Ex.2027 - CA Public Judgment and Reasons | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Ex.2030 - Santen Financial Results | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Ex.2031 - Takagi 2004 | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Ex.2032 - Zioptan Label | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Ex.2034 - Wang 1998 | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Ex.2036 - Aung 2002 | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Ex.2037 - Xalatan Label | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Patent Owner Response | Mar 5, 2018 | PAPER | PATENT OWNER |
Ex.2023 - USP 5977173 | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Ex.2024 - Lee 1985 | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Ex.2028 - Supplemental Macdonald Declaration | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Ex.2029 - Supplemental Fechtner Declaration | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Ex.2033 - Ueno Japan (PO Translation) | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Ex.2035 - Aung 2001 | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Ex.2039 - Lumigan 0.01 Label | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Ex.2040 - Travatan Label | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Ex.2041 - Travatan Z Label | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Ex.2044 - Tapros Medication Guide | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Ex.2045 - Micro Labs Complaint | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Ex.2047 - Dunitz 1997 | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Ex.2048 - Carey 1984 | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Ex.2038 - Lumigan 0.03 Label | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Ex.2042 - Rescula Label | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Ex.2043 - Iopidine Label | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Ex.2046 - Sandoz Complaint | Mar 5, 2018 | EXHIBIT | PATENT OWNER |
Petitioners' Updated Mandatory Notices | Feb 6, 2018 | PAPER | PETITIONER |
Granting Petitioner's Motion for Admission Pro Hac Vice of H. Keeto Sabharwal | Feb 5, 2018 | PAPER | BOARD |
Patent Owners' Notice of Deposition - Rose | Jan 22, 2018 | PAPER | PATENT OWNER |
Patent Owners' Notice of Deposition - deLong | Jan 22, 2018 | PAPER | PATENT OWNER |
MOTION FOR PRO HAC VICE ADMISSION OF H. KEETO SABHARWAL UNDER 37 C.F.R. ¿¿ 42.10(c) | Jan 3, 2018 | PAPER | PETITIONER |
IPR2017-01434 Patent Owners' Objections to Evidence | Dec 18, 2017 | PAPER | PATENT OWNER |
IPR2017-01434 Patent Owners' Objections to Evidence | Dec 13, 2017 | PAPER | PATENT OWNER |
Exhibit 1029 - New Version of Exhibit 1006 with Certified Translation | Dec 11, 2017 | EXHIBIT | PETITIONER |
Petitioners' Updated Exhibit List | Dec 11, 2017 | PAPER | PETITIONER |
Exhibit 1030 - New Version of Exhibit 1007 with Certified Translation | Dec 11, 2017 | EXHIBIT | PETITIONER |
Order Patent Owner's Amended Motion for Admission
Pro Hac Vice of Eric J. Lobenfeld, Esq. | Dec 6, 2017 | PAPER | BOARD |
Trial Instituted Document | Nov 29, 2017 | PAPER | BOARD |
Scheduling Order | Nov 29, 2017 | PAPER | BOARD |
Ex. 2001 - Macdonald Declaration | Sep 7, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2002 - Fechtner Declaration | Sep 7, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2012 - Bito 1987 | Sep 7, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2015 - Camras 1997 | Sep 7, 2017 | EXHIBIT | PATENT OWNER |
Patent Owners' Updated Mandatory Notices | Sep 7, 2017 | PAPER | PATENT OWNER |
Patent Owner Preliminary Response | Sep 7, 2017 | PAPER | PATENT OWNER |
Ex. 2003 - Camras 1977 | Sep 7, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2004 - Xalatan 1996 | Sep 7, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2005 - Fung 2014 | Sep 7, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2006 - Linden 1999 | Sep 7, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2007 - Coleman 1994 | Sep 7, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2008 - Konturek 1986 | Sep 7, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2009 - Stjernschantz 1996 | Sep 7, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2010 - Collins 1993 | Sep 7, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2011 - Giuffre 1985 | Sep 7, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2013 - Villumsen 1989 | Sep 7, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2014 - Villumsen 1990 | Sep 7, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2016 - Camras 1996 | Sep 7, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2017 - EP0364417A1 | Sep 7, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2018 - Qiu 2015 | Sep 7, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2019 - R-Tech Ueno 2009 | Sep 7, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2020 - Schoenwald 1978 | Sep 7, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2021 - Klimko 2004 | Sep 7, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2022 - WO1995026729A1 | Sep 7, 2017 | EXHIBIT | PATENT OWNER |
Amended Motion for Pro Hac Vice Admission of Eric J. Lobenfeld | Jun 14, 2017 | PAPER | PATENT OWNER |
Motion for Pro Hac Vice Admission of Eric J. Lobenfeld | Jun 12, 2017 | PAPER | PATENT OWNER |
Notice of Accord Filing Date | Jun 8, 2017 | PAPER | BOARD |
Patent Owners' Mandatory Notices | Jun 1, 2017 | PAPER | PATENT OWNER |
Power of Attorney - Santen | Jun 1, 2017 | PAPER | PATENT OWNER |
Power of Attorney - AGC | Jun 1, 2017 | PAPER | PATENT OWNER |
Power of Attorney | May 12, 2017 | PAPER | PETITIONER |
Exhibit 1004 - EP0471856A1 to Kishi et al. | May 12, 2017 | EXHIBIT | PETITIONER |
Petition for Inter Partes Review of U.S. Patent No. 5,886,035. | May 12, 2017 | PAPER | PETITIONER |
Exhibit 1001 - U.S. Patent No. 5,886,035 to Shirasawa et al. | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1002 - File History of U.S. Patent No. 5,886,035 to Shirasawa et al. | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1003 - EP0639563A2 to Klimko et al. | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1005 - U.S. Patent No. 5,292,754 to Kishi et al. | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1007 - Bezuglov, V. V. & L. D. Bergelson, ¿¿¿Fluoroprostaglandins¿¿¿A New Class of Biologically Active Analogues of Natural Prostaglandins | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1008 - Bezuglov, Vladimir V. ¿¿¿Fluorodeoxy Prostaglandins, Synthesis and Perspectives | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1010 - Stjernschantz, J.W. ¿¿¿From PGF2-Isopropyl Ester to Latanoprost: A Review of the Development of Xalatan | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1011 - Nixon, D. ¿¿¿Hyperemia in Glaucoma Patients | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1013 - U.S. Provisional Patent Application No. 60/030,519 to Klimko et al. | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1017 - Patent and Exclusivity for: N202514 (ZIOPTAN) | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1018 - Lee, P.Y. et al., ¿¿¿The effect of prostaglandin F2 alpha on intraocular pressure in normotensive human subjects | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1021 - Pederson, J.E. et al., ¿¿¿Laser-induced primate glaucoma | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1023 - Lee, P.Y. et al., ¿¿¿Pharmacological testing in the laser-induced monkey glaucoma model | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1006 - JP-A-7070054 to Ueno Japan et al. | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1009 - Camras et al. Reduction of intraocular pressure in normal and glaucomatous primate (Aotus trivirgatus) | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1012 - PCT/US97/20671 to Klimko et al. | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1014 - Alm A 1989 Progress in Clin and Biological Research | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1015 - Stjernschantz J 1992 Drugs of the Future | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1016 -Product Details for NDA 020597 (XALATAN) | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1019 - Camras, C.B. et al., ¿¿¿Maintained reduction of intraocular pressure by prostaglandin F2 alpha-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1020 - Nilsson, S.F. et al., ¿¿¿Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1022 - Radius, R.L. et al., ¿¿¿Laser-induced primate glaucoma. II. Histopathology | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1024 - Bito | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1026 - Nelson, N.A. ¿¿¿Prostaglandin Nomenclature | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1028 - Declaration of Aron D. Rose, M.D. | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1025 - U.S. Patent No. 3,914,265 to Middleton | May 12, 2017 | EXHIBIT | PETITIONER |
Exhibit 1027 - Declaration of Mitchell deLong, Ph.D. | May 12, 2017 | EXHIBIT | PETITIONER |